This trial is evaluating whether N-803 and BCG will improve 1 primary outcome and 2 secondary outcomes in patients with Bladder Cancer, Cancer. Measurement will happen over the course of 12 Months.
This trial requires 200 total participants across 1 different treatment group
This trial involves a single treatment. N-803 And BCG is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
"The bladder cancer is a locally confined disease, and in an excellent proportion of such patients a complete cytoreductive surgery along with a radical pelvic lymphadenectomy could be performed. In these patients the disease could have been treated by transuranic alpha-irradiation in a good proportion." - Anonymous Online Contributor
"When used in the correct dose, cannabis and its psychoactive compounds do not appear to pose a significant risk of bladder cancer and may play a role in the treatment of bladder cancer by reducing discomfort associated with intravesical immunotherapy." - Anonymous Online Contributor
"Urinary bladder carcinogenesis is typically a multifactorial process. The majority of urothelial bladder cancers present in young patients. The role of tobacco smoking and non-specific aetiologies in the pathogenesis of bladder cancer are hotly debated. The majority of bladder cancers in the UK are superficial malignant urothelial tumours. Patients with high-grade non-muscle-invasive bladder cancer might respond well to intravesical therapy following transurethral resection. Patients with high-grade muscle invasive disease should be considered for more aggressive multimodal protocols." - Anonymous Online Contributor
"No common causes for bladder cancer have been reported. On the other hand, a study on Chinese patients from Taiwan has found evidence that diabetes mellitus can increase the risk of bladder cancer and that an infection with schistosomiasis can be associated with an increased risk for bladder cancer." - Anonymous Online Contributor
"There are 60,800 new diagnoses of urinary bladder cancer. On average, women are diagnosed later than men, and the prevalence of bladder cancer increases with age." - Anonymous Online Contributor
"Urinary bladder cancer is often treated with surgical resection. Surgery can be used to remove only the urinary bladder without resection of surrounding lymph nodes. Radiation is rarely used for localized disease but may be used in locally advanced cases." - Anonymous Online Contributor
"Symptoms of urinary bladder cancer include decreased bladder capacity, urinary frequency, pain in the belly, a desire to urinate at night or frequent leaks from the urinary bladder. Symptoms can also include hematuria, abnormal urine colour, swollen knees, or numbness in the feet." - Anonymous Online Contributor
"The administration of N-803 plus BCG did not significantly improve or interfere with quality of life in this group of patients evaluated in a randomized trial." - Anonymous Online Contributor
"In the context of the NCI-funded CANCER trial, the effect of BCG on cancer-related survival was statistically significant. Results on other outcomes were less convincing. Although the numbers were small, the result that we observed was similar to those we had reported in the earlier CANCER trial. Although there were no differences in PFS or OS between treatment groups, there was no difference in PFS between n-803 and BCG. The conclusion that there were no statistically significant differences in all outcomes is consistent with the existing evidence and suggests that the results may be due to chance. This finding was also consistent with previous CANCER trial results." - Anonymous Online Contributor
"The most important progress has been in detecting and treating bladder cancer in the early stages. Findings from a recent study of randomized controlled trials are awaited to establish the efficacy of various systemic agents, both neoadjuvant and adjuvant." - Anonymous Online Contributor
"N-803, BCG, and combined chemotherapies are typically used in conjunction with other cancer therapies, but their respective effectiveness remains poorly defined. A review of the literature is consistent with the use of N-803, combined chemotherapies (BCG, or with VEGF inhibitors among others), and chemotherapy using methotrexate alone in the setting of advanced UCB. There is little data supporting the use of N-803 and BCG in conjunction with one another. Further studies are warranted to assess the potential benefit of these agents to improve patient outcomes in UCB and to identify patients who are likely to derive greater benefit from treatment regimens that include N-803, BCG, chemotherapy, and radiation." - Anonymous Online Contributor
"Urinary [bladder cancer](https://www.withpower.com/clinical-trials/bladder-cancer) is a heterogeneous neoplasm. Both the presence and absence of cancers in first degree relatives may be useful to identify families of patients with increased risk, thereby providing a useful tool to identify the genetic causes of this disease. This article is protected by copyright. All rights reserved." - Anonymous Online Contributor